Posted by & filed under Company Analysis, Financial analysis, Governments & Regulators, Growth & Valuation.

Description: NEW YORK – Creditors of Valeant Pharmaceuticals International, which has been in violation of lender agreements since Wednesday, are beginning to demand new terms that could further pressure the drugmaker’s business model, according to three people familiar with the matter.


Date: Mar 21, 2016


Questions for Discussions:

  • Do you think the business model is in doubt?
  • How would go about assessing the value of Valeant today?
  • How significant is the risk associated with the debt load?

Leave a Reply

Your email address will not be published. Required fields are marked *